Published in Curr Opin Gastroenterol on July 01, 2014
Irritable bowel syndrome. Nat Rev Dis Prim (2016) 1.14
The utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol (2015) 1.05
Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model. BMC Microbiol (2015) 0.98
Stress-induced visceral pain: toward animal models of irritable-bowel syndrome and associated comorbidities. Front Psychiatry (2015) 0.96
Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye? Therap Adv Gastroenterol (2016) 0.81
Mechanisms by which Stress Affects the Experimental and Clinical Inflammatory Bowel Disease (IBD): Role of Brain-Gut Axis. Curr Neuropharmacol (2016) 0.80
Neuroimmunomodulation in the Gut: Focus on Inflammatory Bowel Disease. Mediators Inflamm (2016) 0.77
Ineffective esophageal motility and the vagus: current challenges and future prospects. Clin Exp Gastroenterol (2016) 0.76
Small Intestinal Bacterial Overgrowth is Associated with Intestinal Inflammation in the Irritable Bowel Syndrome. Clujul Med (2014) 0.75
Identification of Candidate Genes Related to Inflammatory Bowel Disease Using Minimum Redundancy Maximum Relevance, Incremental Feature Selection, and the Shortest-Path Approach. Biomed Res Int (2017) 0.75
Trends in Irritable Bowel Syndrome Incidence among Taiwanese Adults during 2003-2013: A Population-Based Study of Sex and Age Differences. PLoS One (2016) 0.75
Functional gastroduodenal disorders. Gastroenterology (2006) 8.51
Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology (2004) 4.05
Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol (2005) 2.68
Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology (2007) 2.63
Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol (2009) 2.57
Chronic intestinal pseudo-obstruction. World J Gastroenterol (2008) 2.29
A 5-year experience of benign pancreatic hyperenzymemia. Pancreas (2014) 2.27
Inflammatory neuropathies of the enteric nervous system. Gastroenterology (2004) 2.02
Gastroparesis Cardinal Symptom Index (GCSI): development and validation of a patient reported assessment of severity of gastroparesis symptoms. Qual Life Res (2004) 1.88
Enteric neuroplasticity evoked by inflammation. Auton Neurosci (2006) 1.55
Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology (2009) 1.50
Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol (2011) 1.41
Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol (2005) 1.35
Cross-cultural development and validation of a patient self-administered questionnaire to assess quality of life in upper gastrointestinal disorders: the PAGI-QOL. Qual Life Res (2004) 1.26
Clinical and morphofunctional features of idiopathic myenteric ganglionitis underlying severe intestinal motor dysfunction: a study of three cases. Am J Gastroenterol (2002) 1.22
A mutation in telethonin alters Nav1.5 function. J Biol Chem (2008) 1.20
Anti-HuD-induced neuronal apoptosis underlying paraneoplastic gut dysmotility. Gastroenterology (2003) 1.19
Chronic intestinal pseudo-obstruction: clinical features, diagnosis, and therapy. Gastroenterol Clin North Am (2011) 1.18
The immune system in irritable bowel syndrome. J Neurogastroenterol Motil (2011) 1.16
Chronic intestinal pseudo-obstruction. Best Pract Res Clin Gastroenterol (2007) 1.03
Current management strategies and emerging treatments for functional dyspepsia. Nat Rev Gastroenterol Hepatol (2013) 1.03
Responsiveness and interpretation of a symptom severity index specific to upper gastrointestinal disorders. Clin Gastroenterol Hepatol (2004) 1.00
Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome. Curr Gastroenterol Rep (2011) 0.99
Dyspeptic symptoms in primary care. An observational study in general practice. Eur J Gastroenterol Hepatol (2002) 0.99
Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome. J Clin Gastroenterol (2012) 0.99
Italian consensus conference for colonic diverticulosis and diverticular disease. United European Gastroenterol J (2014) 0.97
Postinfectious irritable bowel syndrome. J Pediatr Gastroenterol Nutr (2009) 0.91
5-HT7 receptors modulate peristalsis and accommodation in the guinea pig ileum. Gastroenterology (2005) 0.90
Intestinal transplantation for chronic intestinal pseudo-obstruction in adult patients. Am J Transplant (2004) 0.89
Genetics of human enteric neuropathies. Prog Neurobiol (2012) 0.89
The changing clinical profile of celiac disease: a 15-year experience (1998-2012) in an Italian referral center. BMC Gastroenterol (2014) 0.88
Almost all irritable bowel syndromes are post-infectious and respond to probiotics: controversial issues. Dig Dis (2007) 0.88
Responsiveness and interpretation of a quality of life questionnaire specific to upper gastrointestinal disorders. Clin Gastroenterol Hepatol (2004) 0.88
Biomarkers in IBS: when will they replace symptoms for diagnosis and management? Gut (2009) 0.87
Enteric neuropathology of congenital intestinal obstruction: A case report. World J Gastroenterol (2006) 0.86
The construction of a new evaluative GERD questionnaire - methods and state of the art. Digestion (2004) 0.86
Unfulfilled wishes by gastric electrical stimulation. Clin Gastroenterol Hepatol (2011) 0.86
Aminosalicylates and other anti-inflammatory compounds for irritable bowel syndrome. Dig Dis (2010) 0.85
HOX11L1: a promoter study to evaluate possible expression defects in intestinal motility disorders. Int J Mol Med (2002) 0.85
Neurology and neuropathology of the pancreatic innervation. JOP (2002) 0.85
Expression and regulation of α-transducin in the pig gastrointestinal tract. J Cell Mol Med (2013) 0.85
A novel locus for syndromic chronic idiopathic intestinal pseudo-obstruction maps to chromosome 8q23-q24. Eur J Hum Genet (2007) 0.84
Seasonal pattern of peptic ulcer hospitalizations: analysis of the hospital discharge data of the Emilia-Romagna region of Italy. BMC Gastroenterol (2010) 0.84
Retracted Gut microbiota and related diseases: clinical features. Intern Emerg Med (2010) 0.83
Intestinal dysbiosis in irritable bowel syndrome: etiological factor or epiphenomenon? Expert Rev Mol Diagn (2010) 0.83
Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use. J Clin Gastroenterol (2008) 0.81
The Rome II Criteria for patients with functional gastroduodenal disorders. J Clin Gastroenterol (2003) 0.81
Sympathetic hyperactivity in patients with ulcerative colitis. Clin Auton Res (2007) 0.80
Audit of digestive complaints and psychopathological traits in patients with eating disorders: a prospective study. Dig Liver Dis (2013) 0.80
What is the effect of inflammation on intestinal function? Inflamm Bowel Dis (2008) 0.80
Clinical approach to diarrhea. Intern Emerg Med (2012) 0.80
A possible role of food intolerance in the pathogenesis of gastroesophageal reflux disease. Am J Gastroenterol (2009) 0.80
Autoimmune Hepatitis and Celiac Disease: Case Report Showing an Entero-Hepatic Link. Case Rep Gastroenterol (2010) 0.80
Rifaximin and diverticular disease: Position paper of the Italian Society of Gastroenterology (SIGE). Dig Liver Dis (2017) 0.79
GERD 2003 -- a consensus on the way ahead. Digestion (2003) 0.79
Herpes simplex virus type 1 infection of the rat enteric nervous system evokes small-bowel neuromuscular abnormalities. Gastroenterology (2010) 0.78
Norovirus gastroenteritis. N Engl J Med (2010) 0.78
Neurogenic chronic intestinal pseudo-obstruction: antineuronal antibody-mediated activation of autophagy via Fas. Gastroenterology (2008) 0.78
Neuroimmune interaction and anorectal motility in children with food allergy-related chronic constipation. Am J Gastroenterol (2009) 0.77
Contrast-enhanced ultrasound in the differential diagnosis of exocrine versus neuroendocrine pancreatic tumors. Pancreas (2013) 0.77
Editorial: Reflux, dyspepsia, and Rome III (or Rome IV?). Am J Gastroenterol (2010) 0.77
The construction of a new evaluative GERD questionnaire--methods and state of the art. Digestion (2007) 0.76
Serine proteases: new players in diarrhoea-predominant irritable bowel syndrome. Gut (2008) 0.76
Sigmoid compliance and visceral perception in spinal cord injury patients. Eur J Gastroenterol Hepatol (2012) 0.76
A case of paraneoplastic inflammatory neuropathy of the gastrointestinal tract related to an underlying neuroblastoma: successful management with immunosuppressive therapy. J Pediatr Gastroenterol Nutr (2008) 0.76
Antiflagellin antibodies suggest infective participation in irritable bowel syndrome pathogenesis. Expert Rev Gastroenterol Hepatol (2008) 0.76
Does colorectal endometriosis alter intestinal functions? A prospective manometric and questionnaire-based study. Fertil Steril (2012) 0.76
Efficacy and tolerability of α-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial. BMC Gastroenterol (2013) 0.75
Transcriptional regulation of TLX2 and impaired intestinal innervation: possible role of the PHOX2A and PHOX2B genes. Eur J Hum Genet (2007) 0.75
Detection of anticonductive tissue autoantibodies in a patient with chronic intestinal pseudo-obstruction and sick sinus syndrome. Eur J Gastroenterol Hepatol (2013) 0.75
Benign Pancreatic Hyperenzymemia: Lights on a Clinical Challenge. Pancreas (2017) 0.75
How relevant is symptom evaluation in NERD? Digestion (2008) 0.75
Prokinetics in the treatment of acute intestinal pseudo-obstruction. IDrugs (2004) 0.75
Treatment of Diverticular Disease With Aminosalicylates: The Evidence. J Clin Gastroenterol (2016) 0.75
Drug rash with eosinophilia and systemic symptoms secondary to phenobarbitone. Clin Neuropharmacol (2003) 0.75